Last reviewed · How we verify
Experimental drug: Olanzapine
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Treatment-resistant depression (adjunctive use).
At a glance
| Generic name | Experimental drug: Olanzapine |
|---|---|
| Sponsor | CCTU |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its broader pharmacological profile.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Treatment-resistant depression (adjunctive use)
Common side effects
- Weight gain
- Sedation
- Metabolic syndrome/hyperglycemia
- Hyperlipidemia
- Akathisia
- Orthostatic hypotension
- Prolactin elevation
Key clinical trials
- Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (PHASE3)
- Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants (PHASE3)
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (PHASE3)
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Alleviating the Metabolic Side Effects of Antipsychotic Medications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental drug: Olanzapine CI brief — competitive landscape report
- Experimental drug: Olanzapine updates RSS · CI watch RSS
- CCTU portfolio CI